SPOTLIGHT -
May 1st 2024
The non-randomized, open label, safety and efficacy study will inject a sustained release implant in 5 participants.
April 23rd 2024
OCU410 utilizes an AAV delivery platform for the retinal delivery of the RORA gene, the company stated in a news release.
April 11th 2024
The Phase 1/2 study includes a dose-escalation phase of the study featuring 3 cohorts each one receiving either a low, medium, or high dose of OCU410.
March 27th 2024
Since its U.S. launch in September 2023, more than 40,000 avacincaptad pegol intravitreal solution vials have been distributed to physician practices.
March 25th 2024
The Phase 2 trial tested whether inhibiting microglia with minocycline might help slow GA expansion and its corresponding vision loss.
Geographic atrophy: What to know and why
Look out for at-risk patients and prepare to establish treatment protocols.
Apellis aims to submit 24-month Phase 3 data to FDA for pegcetacoplan NDA
The submission of 24-month efficacy data from DERBY and OAKS is classified as a Major Amendment to the New Drug Application, which delays the PDUFA target action date until February 2023.
Apellis releases 24-month results of phase 3 studies for GA treatment
Latest data from phase 3 studies finds increased effects over time with intravitreal pegcetacoplan for geographic atrophy secondary to age-related macular degeneration.
Apellis receives FDA acceptance, priority review of NDA for GA treatment
If approved, pegcetacoplan—an investigational, targeted C3 therapy—will be the first-ever treatment for GA.
Imaging technology helps in scanning for retinal diseases
Advancements enable better diagnosis, treatment of patients.
Apellis submits NDA to FDA for geographic atrophy treatment
A decision by the FDA is expected in August 2022.
What’s hot (and not) in retinal news
A look at the latest developments in retinal disease, including clinical trials and advanced therapies.
Apellis releases 18-month results from phase 3 studies of pegcetacoplan for GA
New detailed, longer-term findings were presented at the 2022 ARVO meeting.